Target intelligence / Profile preview

RNA, U6 small nuclear 250, pseudogene (RNU6-250P)

Target
RNU6-250P
Molecular classification
Other, Pseudogene
01

Overview

RNA, U6 small nuclear 250, pseudogene (RNU6-250P) is classified as a **pseudogene** of the U6 small nuclear RNA (snRNA) family[3]. U6 snRNA itself is a highly conserved and essential component of the spliceosome, the molecular machine responsible for pre-mRNA splicing in the nucleus[1][2]. The active U6 snRNA is critical for the catalysis of intron removal from pre-mRNA, is subject to post-transcriptional modifications, and interacts with core spliceosomal proteins and RNAs[1][2]. However, as a pseudogene, RNU6-250P does **not produce a functional RNA or protein product** and lacks the typical biological activity or relevance as a molecular target[3]. Pseudogenes are generally considered non-functional genomic elements arising from duplication or retrotransposition events and do not participate in cellular processes or disease mechanisms relevant to drug targeting. Key points: - RNU6-250P is a **pseudogene**, not a functional gene[3]. - It does **not encode a functional snRNA**, protein, or therapeutic target[3]. - It has no known biological function, disease association, interacting drugs, or relevance as a biomarker or therapeutic target. - The primary U6 snRNA gene (separate from pseudogenes) is an essential player in the splicing machinery, but these properties do not apply to pseudogenes[1][2]. - There is nothing indicating misspelling, but as a pseudogene, it is not a legitimate drug target. For structured data extraction, only the **main U6 snRNA gene** would be relevant as a molecular target, not the RNU6-250P pseudogene.

Other names
RNU6-250P

Beyond the preview

Go deeper on RNA, U6 small nuclear 250, pseudogene (RNU6-250P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6 small nuclear 250, pseudogene (RNU6-250P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call